当前位置 : 首页 > 市场合作 > 项目信息市场合作
Market cooperation| 发包方名称 | National Hospital Organization - Miyagi |
| 发包方国别(国家/地区) | 日本 |
| 发包方座机 | |
| 发包方传真 | |
| 发包方邮箱 | |
| 发包方地址 | Director, Accounting Division, National Hospital Organization Sendai Medical Center, 2-11-12 Miyagino Miyaginoku Sendai-shi Miyagi-ken 983-8520, Japan |
| 发包方网址 | |
| 发包方联系人姓名 | Ryo Sasaki |
| 发包方联系人座机 | 022-293-1111 |
| 发包方联系人手机 | |
| 发包方联系人邮箱 | |
| 项目名称 | ULTOMIRIS for Intravenous Infusion 300mg Planned quantity 364,and 12 other contracts |
| 项目类型 | 其他 - 其他 |
| 项目预算￥ | |
| 项目投标截止时间 | 2021-09-27 |
| 项目开始时间 | |
| 项目结束时间 | |
| 服务商资质要求 | |
| 要求高匹配度成功案例个数 | |
| 项目交付地点 | |
| 是否准许转包或分包 | |
| 项目信息详述 |
⑴ Classification of the products to be procured : 4
⑵ Nature and quantity of the products to be purchased :
① ULTOMIRIS for Intravenous Infusion 300mg Planned quantity 364
② SOLIRIS for Intravenous Infusion 300mg Planned quantity 229
③ Revlimid Capsules 5mg Planned quantity 540
④ Pomalyst Capsules 4mg Planned quantity 160
⑤ Pomalyst Capsules 3mg Planned quantity 124
⑥ Pomalyst Capsules 2mg Planned quantity 102
⑦ TREAKISIM Injection Solution 100mg/4㎖ Planned quantity 400
⑧ SARCLISA I.V. Infusion 500mg Planned quantity 64
⑨ IMBRUVICA Capsules 140mg Planned quantity 181
⑩ HEMLIBRA for Subcutaneous Injection 150mg Planned quantity 157
⑪ HEMLIBRA for Subcutaneous Injection 90mg Planned quantity 153
⑫ HEMLIBRA for Subcutaneous Injection 105mg Planned quantity 105
⑬ HEMLIBRA for Subcutaneous Injection 60mg Planned quantity 98
⑶ Expected date of the contract award : September 27, 2021
⑷ Reasons for the use of single tendering procedures as provided for in the Agreement on Government Procurement : b "Absence of Competition for Technical Reasons"
⑸ Contact point for the notice : Ryo Sasaki, Director, Accounting Division, National Hospital Organization Sendai Medical Center, 2-11-12 Miyagino Miyaginoku Sendai-shi Miyagi-ken 983-8520, Japan. TEL 022-293-1111
|
版权所有：天津市数字贸易综合服务平台 备案号：津B2-20080229-9
联系人：高杨 
手机：+86-131-1480-9286 
邮箱：gloria.gao@devott.com 
微信：13114809286 
